BR112016018978B1 - Método para medir atividade enzimática lisossomal - Google Patents
Método para medir atividade enzimática lisossomal Download PDFInfo
- Publication number
- BR112016018978B1 BR112016018978B1 BR112016018978-7A BR112016018978A BR112016018978B1 BR 112016018978 B1 BR112016018978 B1 BR 112016018978B1 BR 112016018978 A BR112016018978 A BR 112016018978A BR 112016018978 B1 BR112016018978 B1 BR 112016018978B1
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- lysosomal enzyme
- substrate
- lysosomal
- sample
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 75
- 230000002255 enzymatic effect Effects 0.000 title claims description 10
- 102000004190 Enzymes Human genes 0.000 claims abstract description 167
- 108090000790 Enzymes Proteins 0.000 claims abstract description 167
- 230000002132 lysosomal effect Effects 0.000 claims abstract description 131
- 239000000758 substrate Substances 0.000 claims abstract description 81
- 208000015439 Lysosomal storage disease Diseases 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 154
- 230000002285 radioactive effect Effects 0.000 claims description 46
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 13
- 230000004700 cellular uptake Effects 0.000 claims description 12
- 102000005262 Sulfatase Human genes 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 108060007951 sulfatase Proteins 0.000 claims description 11
- 230000001419 dependent effect Effects 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 231100000673 dose–response relationship Toxicity 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 5
- 108010089932 heparan sulfate sulfatase Proteins 0.000 claims description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- -1 glycosamine glycan Chemical class 0.000 claims description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 4
- 235000011152 sodium sulphate Nutrition 0.000 claims description 4
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 claims description 3
- 108010060309 Glucuronidase Proteins 0.000 claims description 3
- 102000053187 Glucuronidase Human genes 0.000 claims description 3
- 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 claims description 3
- 101710202061 N-acetyltransferase Proteins 0.000 claims description 3
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 claims description 3
- 239000012298 atmosphere Substances 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 229940126534 drug product Drugs 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims description 2
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 55
- 238000012360 testing method Methods 0.000 abstract description 16
- 238000001514 detection method Methods 0.000 abstract description 5
- 230000001413 cellular effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 41
- 229920002683 Glycosaminoglycan Polymers 0.000 description 24
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 description 10
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000007405 data analysis Methods 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 210000003712 lysosome Anatomy 0.000 description 6
- 230000001868 lysosomic effect Effects 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 5
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 5
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000002641 enzyme replacement therapy Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 102100027165 Alpha-2-macroglobulin receptor-associated protein Human genes 0.000 description 2
- 101710126837 Alpha-2-macroglobulin receptor-associated protein Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 102000056067 N-acetylglucosamine-6-sulfatases Human genes 0.000 description 2
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 2
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000013584 assay control Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000012203 high throughput assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004216 mammary stem cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000011165 process development Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 150000005072 1,3,4-oxadiazoles Chemical class 0.000 description 1
- QKLPIYTUUFFRLV-YTEMWHBBSA-N 1,4-bis[(e)-2-(2-methylphenyl)ethenyl]benzene Chemical compound CC1=CC=CC=C1\C=C\C(C=C1)=CC=C1\C=C\C1=CC=CC=C1C QKLPIYTUUFFRLV-YTEMWHBBSA-N 0.000 description 1
- XJKSTNDFUHDPQJ-UHFFFAOYSA-N 1,4-diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=C(C=2C=CC=CC=2)C=C1 XJKSTNDFUHDPQJ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CNRNYORZJGVOSY-UHFFFAOYSA-N 2,5-diphenyl-1,3-oxazole Chemical compound C=1N=C(C=2C=CC=CC=2)OC=1C1=CC=CC=C1 CNRNYORZJGVOSY-UHFFFAOYSA-N 0.000 description 1
- FCNCGHJSNVOIKE-UHFFFAOYSA-N 9,10-diphenylanthracene Chemical compound C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1C1=CC=CC=C1 FCNCGHJSNVOIKE-UHFFFAOYSA-N 0.000 description 1
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- XZCJVWCMJYNSQO-UHFFFAOYSA-N butyl pbd Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NN=C(C=2C=CC(=CC=2)C=2C=CC=CC=2)O1 XZCJVWCMJYNSQO-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 229930184652 p-Terphenyl Natural products 0.000 description 1
- GPRIERYVMZVKTC-UHFFFAOYSA-N p-quaterphenyl Chemical group C1=CC=CC=C1C1=CC=C(C=2C=CC(=CC=2)C=2C=CC=CC=2)C=C1 GPRIERYVMZVKTC-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002102 polyvinyl toluene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461941365P | 2014-02-18 | 2014-02-18 | |
| US61/941,365 | 2014-02-18 | ||
| PCT/US2015/016394 WO2015126953A1 (en) | 2014-02-18 | 2015-02-18 | Substrate clearance assays for lysosomal enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016018978A2 BR112016018978A2 (enExample) | 2017-08-15 |
| BR112016018978B1 true BR112016018978B1 (pt) | 2024-03-12 |
Family
ID=52649105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016018978-7A BR112016018978B1 (pt) | 2014-02-18 | 2015-02-18 | Método para medir atividade enzimática lisossomal |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11187697B2 (enExample) |
| EP (1) | EP3108258B1 (enExample) |
| JP (1) | JP6684715B2 (enExample) |
| CN (1) | CN105980859B (enExample) |
| AU (1) | AU2015219097B2 (enExample) |
| BR (1) | BR112016018978B1 (enExample) |
| CA (1) | CA2938498A1 (enExample) |
| EA (1) | EA201691393A1 (enExample) |
| MX (1) | MX373640B (enExample) |
| WO (1) | WO2015126953A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11396499B2 (en) | 2018-12-12 | 2022-07-26 | University Of Washington | Lysosomal acid lipase assay |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0650396T3 (da) * | 1993-05-17 | 1998-09-14 | Amersham Int Plc | Udstyr og fremgangsmåde til måling af celluære biokemiske processer. |
| DK1007971T3 (da) * | 1997-08-18 | 2004-12-06 | Amersham Plc | Scintillationsproximitetstest |
| AR034413A1 (es) * | 2000-08-25 | 2004-02-25 | Nestor Abel Chamoles | Metodo para determinar la actividad de las enzimas lisosomales |
| US20050244907A1 (en) * | 2003-12-15 | 2005-11-03 | Applera Corporation | Methods, compositions, and kits for analysis of enzyme activity in cells |
| WO2009006877A2 (de) | 2007-07-06 | 2009-01-15 | Papst Licensing Gmbh & Co. Kg | Bestimmung der aktivität von proteasen |
| MX2010007846A (es) * | 2008-01-18 | 2010-10-05 | Biomarin Pharm Inc | Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas. |
| WO2011100392A2 (en) * | 2010-02-10 | 2011-08-18 | Nova Southeastern University | Methionine gamma lyase-2-aminobutyrate (megl-2abd) and therapeutic uses thereof |
-
2015
- 2015-02-18 JP JP2016551191A patent/JP6684715B2/ja active Active
- 2015-02-18 MX MX2016010719A patent/MX373640B/es active IP Right Grant
- 2015-02-18 AU AU2015219097A patent/AU2015219097B2/en active Active
- 2015-02-18 WO PCT/US2015/016394 patent/WO2015126953A1/en not_active Ceased
- 2015-02-18 EP EP15709389.9A patent/EP3108258B1/en active Active
- 2015-02-18 CA CA2938498A patent/CA2938498A1/en not_active Abandoned
- 2015-02-18 BR BR112016018978-7A patent/BR112016018978B1/pt active IP Right Grant
- 2015-02-18 US US15/119,324 patent/US11187697B2/en active Active
- 2015-02-18 EA EA201691393A patent/EA201691393A1/ru unknown
- 2015-02-18 CN CN201580008136.XA patent/CN105980859B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11187697B2 (en) | 2021-11-30 |
| EP3108258A1 (en) | 2016-12-28 |
| WO2015126953A1 (en) | 2015-08-27 |
| CN105980859A (zh) | 2016-09-28 |
| JP2017506508A (ja) | 2017-03-09 |
| MX2016010719A (es) | 2016-11-23 |
| BR112016018978A2 (enExample) | 2017-08-15 |
| EP3108258B1 (en) | 2019-12-04 |
| CN105980859B (zh) | 2018-10-19 |
| AU2015219097A1 (en) | 2016-08-18 |
| AU2015219097B2 (en) | 2021-02-11 |
| CA2938498A1 (en) | 2015-08-27 |
| MX373640B (es) | 2020-05-04 |
| EA201691393A1 (ru) | 2016-12-30 |
| US20170219566A1 (en) | 2017-08-03 |
| JP6684715B2 (ja) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andrysiak et al. | Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research | |
| Davis et al. | Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development | |
| US10829727B2 (en) | Engineered platform to generate 3D cardiac tissues | |
| Wang et al. | MicroRNA-193 pro-proliferation effects for bone mesenchymal stem cells after low-level laser irradiation treatment through inhibitor of growth family, member 5 | |
| Rando et al. | The fate of myoblasts following transplantation into mature muscle | |
| CN101400697B (zh) | 寻常鱼鳞病、特异反应性和其他病症的预防/治疗 | |
| Tsvetkova et al. | γH2AX, 53BP1 and Rad51 protein foci changes in mesenchymal stem cells during prolonged X-ray irradiation | |
| Krenning et al. | Time-resolved single-cell sequencing identifies multiple waves of mRNA decay during the mitosis-to-G1 phase transition | |
| Viganò et al. | Tips and tricks for validation of quality control analytical methods in good manufacturing practice mesenchymal stromal cell production | |
| Jansen et al. | Mammalian polymerase ζ is essential for post-replication repair of UV-induced DNA lesions | |
| Kaupp et al. | Mechanical stimulation of chondrocyte-agarose hydrogels | |
| Giménez et al. | Elastic properties of hydrogels and decellularized tissue sections used in mechanobiology studies probed by atomic force microscopy | |
| Van Zwieten et al. | Assessing dystrophies and other muscle diseases at the nanometer scale by atomic force microscopy | |
| NZ576360A (en) | Marker genes for use in the identification of chondrocyte phenotypic stability and in the screening of factors influencing cartilage production | |
| Smith et al. | Selected contribution: mechanical strain increases force production and calcium sensitivity in cultured airway smooth muscle cells | |
| Wachsberger et al. | Rejoining of DNA double-strand breaks in Ku80-deficient mouse fibroblasts | |
| Mainardi et al. | An Organ‐on‐Chip Platform for Strain‐Controlled, Tissue‐Specific Compression of Cartilage and Mineralized Osteochondral Interface to Study Mechanical Overloading in Osteoarthritis | |
| BR112016018978B1 (pt) | Método para medir atividade enzimática lisossomal | |
| Otsuka et al. | Comparative quantification method for glycosylated products elongated on β-xylosides using a stable isotope-labeled saccharide primer | |
| US20060003311A1 (en) | In vitro screening of cellular events using 3d cell culture systems | |
| Macadangdang et al. | Engineered developmental niche enables predictive phenotypic screening in human dystrophic cardiomyopathy | |
| Tong et al. | Glioblastoma cells imitate neuronal excitability in humans | |
| US20090305905A1 (en) | Compositions and methods relating to characterization and therapeutic application of pristine stem cells | |
| Le et al. | An optimized O9-1/hydrogel system for studying mechanical signals in neural crest cells | |
| Yao et al. | Biomimetic model for the identification of distinctive microenvironmental factors in glioblastoma radiosensitivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
| B25B | Requested transfer of rights rejected |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870210053303 DE 14/06/2021, EM VIRTUDE DA SOLICITACAO JA TER SIDO ATENDIDA PELA PETICAO 870210050551 DE 04/06/2021. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/2015, OBSERVADAS AS CONDICOES LEGAIS |